Online inquiry

IVTScrip™ mRNA-Anti-pagA, ETI-204(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6988MR)

This product GTTS-WQ6988MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets pagA gene. The antibody can be applied in Anthrax research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq WP_000746486.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 45025512
UniProt ID P13423
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-pagA, ETI-204(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6988MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ11848MR IVTScrip™ mRNA-Anti-TIGIT, MK-7684(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MK-7684
GTTS-WQ7475MR IVTScrip™ mRNA-Anti-TGFB, GC-1008(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GC-1008
GTTS-WQ15899MR IVTScrip™ mRNA-Anti-IL1B, XOMA 052(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA XOMA 052
GTTS-WQ9850MR IVTScrip™ mRNA-Anti-ICOS, JTX-2011(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA JTX-2011
GTTS-WQ6063MR IVTScrip™ mRNA-Anti-CCL2, CNTO 888(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CNTO 888
GTTS-WQ58MR IVTScrip™ mRNA-Anti-TNFRSF17, 2857916(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 2857916
GTTS-WQ9236MR IVTScrip™ mRNA-Anti-MUC1, IMMU-107(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IMMU-107
GTTS-WQ13408MR IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PRO132365
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW